ClinicalTrials.gg
CompletedNCT06192173Updated Jan 9, 2024

Patent Foramen Ovale Closure in Migraine

An observational study in Migraine and Patent Foramen Ovale, sponsored by Haiyan Wang. Completed at 1 site in China. Per ClinicalTrials.gov, last updated 2024-01-09.

Sponsored by Haiyan Wang · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
138
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 80 studies in Migraine Disorders with a site in China — 34 open to participants now, 40 under way, 10 of them phase 3. Migraine Disorders · China.

Enrollment
16th of 19
138 · median 330
Started
2022
with 9 others
Observational
19 of 80
9 open now
Registered
48th of 80
by date

Among the 80 studies in Migraine Disorders with a site in China, this one is the 16th largest by enrollment of the 19 observational ones that give a count, is one of 10 that started in 2022, is one of 19 observational ones, and was the 48th registered.

Migraine Disorders

1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

34 of the 80 studies in Migraine Disorders with a site in China are open now. Recruiting first, the newest first:

29 more — sign in →

All 34 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Migraine Disorders with a site in China, or all of them as a file.
02

Study summary

The goal of this observational study is to retrospectively observe the effect of PFO closure and medication on migraine. The main questions it aims to answer are:

  • Whether PFO closure is more effective in the treatment of migraine than traditional medical treatment
  • What factors affect the effectiveness of migraine treatment ?

Participants will undergo contrast transthoracic echocardiography to diagnose PFO and evaluate right-to-left shunt. They will be treated with medication and PFO closure respectively according to guidelines. HIT-6 and a questionnaire about migraine were obtained at the baseline and repeated at the 6-month and 12-month follow-up visits.

Researchers will compare closure group and drug group to see efficacy of two groups in treating migraine.

Read the detailed description

Migraine patients with PFO who were admitted to our hospital from January 2018 to August 2021 were enrolled.They will be treated with medication and PFO closure respectively according to guidelines. Headache impact test (HIT-6) and a questionnaire about migraine were obtained at the baseline and repeated at the 6th and 12th month follow-up visits.

  1. HIT-6 was used to assess migraine severity.
  2. Questionnaire included questions regarding average duration of migraine, migraine frequency, relief of migraine after treatment, family history and medication use.
  3. △HIT-6 is the difference between baseline and follow-up in HIT-6 and is used to assess migraine relief. The days of migraine attacks per month (MAD) were calculated by the product of the frequency of headache attacks and average duration of each attack. Therefore, the days of migraine remission per month (MRD)= MAD at the 6th or 12th month follow-up- MAD at baseline. In comparison with baseline, 50% decrease in the number of total attacks was considered responder.
  4. Four parameters were selected to evaluate the treatment effect: HIT-6, △HIT-6, MRD, and response rate.
03

Conditions studied

  • Migraine
  • Patent Foramen Ovale
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Migraine patients who diagnosed with PFO and HIT-6 ≥50

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Closure group:

  • Migraine patients with grade II-III RLS of PFO confirmed by cTTE.
  • HIT-6≥50.
  • Meeting the surgical indications of PFO closure according to Chinese expert consensus on Prophylactic Closure of Patent foramen ovale published in March 2017
  • Patients who have underwent PFO closure.

Drug group:

  • Migraine patients with grade II-III RLS of PFO confirmed by cTTE.
  • HIT-6 ≥ 50.
  • Patients who have underwent drug treatment for 12 months.

Exclusion criteria

Exclusion Criteria:

  • Congenital heart diseases, cardiomyopathy, heart failure, valvular heart disease, arrhythmia, severe hypertension or other heart diseases.
  • Patients with serious complications after closure.
  • Patients who have other known triggers of migraine.
  • Patients with incomplete follow-up data.
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
138 participants (actual)
Patient registry
No

Groups and cohorts

  • Closure group

    Migraine patients with PFO who managed with percutaneous PFO closure.

    Procedure: Percutaneous PFO closure

  • Drug group

    Migraine patients with PFO who treated with medicion.

Interventions

  • ProcedurePercutaneous PFO closure

    Two kinds of interventional closure methods including DSA-guided and TEE-guided percutaneous intervention were performed on closure group.

06

What researchers measure

Primary outcomes

  1. Headache impact test (HIT-6)

    HIT-6 is a self-report assessment tool that covers six dimensions (pain, social functioning, role functioning, vitality, cognitive functioning, and psychological distress) and widely used in headache impact surveys. Scores range from 36-78, \< 49 indicating no effect, 50\~55 some effect, 56\~60 a relatively large effect, and \> 60 severe effect. The higher HIT-6, the more severe the impact of headache on patients.

    Time frame: After recruiting, HIT-6 will be assessed and reported up to 12 weeks.

  2. The days of migraine remission (MRD)

    The days of migraine attacks per month (MAD) were calculated by the product of the frequency of headache attacks and average duration of each attack. Therefore, the days of migraine remission per month (MRD)= MAD at the 6th or 12th month follow-up- MAD at baseline

    Time frame: After recruiting, MRD will be assessed and reported up to 12 weeks.

07

Study locations

1 site
  • The First Affiliated Hospital of Shandong First Medical University
    Jinan, 250000, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2022 to primary completion in Dec 2022, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2023
First posted
Jan 5, 2024
StartActual
Sep 5, 2022
Primary completionActual
Dec 20, 2022
CompletionActual
May 20, 2023
Last update
Jan 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06192173
Lead sponsor
Haiyan Wang
Responsible party
Haiyan Wang (Director, Qianfoshan Hospital) — Sponsor-investigator
First posted
Jan 5, 2024
Start date
Sep 5, 2022
Primary completion
Dec 20, 2022
Completion
May 20, 2023
Last update
Jan 9, 2024

Study contacts

Haiyan Wang
principal investigator · The First Affiliated Hospital of Shandong First Medical University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion